Atomwise
221 Main Street, Suite 1350
San Francisco
California
94105
United States
Website: http://www.atomwise.com/
21 articles with Atomwise
-
Atomwise Appoints Gavin Hirst, Ph.D., as Chief Scientific Officer
9/14/2022
Atomwise , a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced the appointment of Gavin Hirst, Ph.D., as Chief Scientific Officer.
-
In the second half of the calendar year, the biopharma industry continues to ascend in mergers and acquisitions, new drug approvals and big investments, indicate market confidence and growth.
-
Atomwise inked a strategic research-and-development deal with Sanofi to use the AtomNet platform to identify and research up to five drug targets.
-
Recent technological advancements have pushed pharma employees to embrace new technologies and innovations in different areas.
-
Atomwise Adds Pharma Luminaries to Board of Directors and Scientific Advisory Board
6/17/2021
Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB).
-
In a list of the most innovative vaccine makers in 2021, Fast Company has outlined 10 biotech companies that continue to revolutionize the drug-discovery landscape.
-
Atomwise Announces Growing Portfolio of Joint Venture Companies
12/21/2020
Atomwise, the leader in using artificial intelligence for small-molecule drug discovery, unveiled its growing portfolio of emerging joint venture companies with research programs spanning oncology, immunology, infectious disease, neuroscience and clotting disorders.
-
Atomwise Partners with Global Research Teams to Pursue Broad-Spectrum Treatments Against COVID-19 and Future Coronavirus Outbreaks
5/21/2020
Atomwise democratizes access to its advanced AI technology with 15 research collaborations underway to enable academic researchers to discover novel therapies for this pandemic and those in the future.
-
Atomwise and Bridge Biotherapeutics Sign $1B Deal to Unlock Blockbuster Potential in Inflammation
3/9/2020
The collaboration will discover and develop up to 13 small molecule programs, initially targeting Pellino proteins to treat multiple indications
-
BioMotiv and Atomwise Sign AI Partnership to Transform Therapeutic Development
1/13/2020
Strategic collaboration to integrate AI technology, drug development expertise and ecosystem of partners for the commercialization of promising early-stage research
-
Atomwise Announces Largest China-US Collaboration for AI Drug Discovery
9/12/2019
Atomwise could receive up to US$1.5 billion to develop first in-class and best in-class small molecules
-
Hansoh Pharma and Atomwise Launch Strategic AI Drug Discovery Collaboration for Multiple Therapeutic Areas
9/11/2019
Hansoh Pharma to innovate using artificial intelligence (AI) technology to generate first in-class and best in-class small molecules.
-
Atomwise and Atropos Launch Joint Venture to Discover Senescence Modulating Small Molecules for Cancer Patients
9/11/2019
Atomwise Inc., a leader in artificial intelligence (AI) for drug discovery, and Atropos Therapeutics, Inc., a senescence platform discovery company, announced today that they will launch a joint venture company to discover and advance a pipeline of compounds for promising discovery targets for the treatment of cancer.
-
SEngine Precision Medicine and Atomwise Announce Strategic Joint Venture to Accelerate Novel Drug Discovery
9/10/2019
Joint venture brings together AI technology and living tumor organoids to develop novel personalized therapies for cancer patients
-
Atomwise and OncoStatyx Announce Joint Venture to Develop Small Molecule Inhibitors of Oncology Target KDM5B
9/10/2019
Atomwise, Inc. announced the launch of a joint venture with OncoStatyx, LLC, an oncology focused preclinical stage biotechnology company based in Ohio.
-
Research Collaboration Between U-M and Atomwise to Accelerate Drug Discovery Using Innovative Artificial Intelligence Approach
7/10/2019
Michigan Medicine researchers are Alan Smrcka, Ph.D., U-M Department of Pharmacology and Daniel Lawrence, Ph.D., Department of Internal Medicine, Cardiovascular Medicine
-
Atomwise and Enamine to Advance Pediatric Oncology With the World’s First and Largest Ten Billion Compound Virtual Screen
6/24/2019
Atomwise, Enamine, and top university researchers collaborate to discover novel small molecules for the treatment of pediatric cancers using the power of AI and novel chemistry.
-
Atomwise Announces Multi-year, Multi-target Agreement with Lilly for AI-Driven Drug Discovery Program
6/3/2019
The companies will collaborate on up to ten drug targets selected by Lilly, with the goal of accelerating the time it takes to identify and develop potential new medicines.
-
DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases
4/16/2019
Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development
-
Charles River Laboratories and Atomwise Form a Strategic Alliance to Provide Integrated, Artificial Intelligence-Driven Drug Discovery
1/11/2019
Charles River reaffirms commitment to the future of drug discovery by advancing the Company’s integrated, innovative early-stage platform